Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

西妥昔单抗 医学 福克斯 内科学 结直肠癌 肿瘤科 养生 人口 化疗方案 化疗 外科 奥沙利铂 癌症 环境卫生
作者
De‐Shen Wang,Chao Ren,Shan-Shan Li,William Pat Fong,Xiaojun Wu,Jian Xiao,Binkui Li,Yun Zheng,Peirong Ding,Gong Chen,Miao‐Zhen Qiu,Zhi‐Qiang Wang,Feng‐Hua Wang,Hui Luo,Feng Wang,Xiaozhong Wang,Ling-Yun Wang,De-Jin Xie,Tao Chen,Li Li
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:21 (5): e1004389-e1004389 被引量:26
标识
DOI:10.1371/journal.pmed.1004389
摘要

BACKGROUND: It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. METHODS AND FINDINGS: This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI (n = 72) or cetuximab plus FOLFOX (n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus ≥5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann-Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade ≥ 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade ≥ 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. CONCLUSIONS: The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03493048.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
俏皮以旋发布了新的文献求助10
刚刚
1秒前
1秒前
罗小黑完成签到 ,获得积分10
2秒前
小黄的主人完成签到,获得积分20
2秒前
科研白完成签到,获得积分10
3秒前
3秒前
3秒前
科研白发布了新的文献求助10
6秒前
miqi完成签到,获得积分10
6秒前
2026221709发布了新的文献求助10
7秒前
dxftx发布了新的文献求助10
7秒前
8秒前
贾文浩发布了新的文献求助10
8秒前
每㐬山风发布了新的文献求助10
9秒前
Owen的应助被康少采纳,获得10
9秒前
女孩发布了新的文献求助30
10秒前
null的应助被科研通管家采纳,获得10
11秒前
TYH关闭了TYH的文献求助
11秒前
11秒前
田様的应助被科研通管家采纳,获得10
12秒前
12秒前
一颗苹果的应助被科研通管家采纳,获得10
12秒前
12秒前
科研通AI6.2的应助被cc采纳,获得10
12秒前
传奇3的应助被科研通管家采纳,获得10
12秒前
12秒前
楚轩之圣的应助被科研通管家采纳,获得10
12秒前
Hello的应助被科研通管家采纳,获得10
12秒前
Maestro_S的应助被科研通管家采纳,获得10
12秒前
风吹麦浪的应助被科研通管家采纳,获得10
12秒前
Ava的应助被科研通管家采纳,获得10
13秒前
一颗苹果的应助被科研通管家采纳,获得10
13秒前
13秒前
初景的应助被科研通管家采纳,获得20
13秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
13秒前
上官若男的应助被科研通管家采纳,获得10
13秒前
13秒前
疯狂加载ing的应助被369ninja采纳,获得10
14秒前
乐乐的应助被剪头采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573479
关于积分的说明 21831986
捐赠科研通 7781752
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962